Intra-Cellular Therapies: Q4 Earnings Insights

Intra-Cellular Therapies ITCI reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM.

Here's what investors need to know about the announcement.

Intra-Cellular Therapies missed estimated earnings by 5.0%, reporting an EPS of $-1.05 versus an estimate of $-1.0.

Revenue was up $13.22 million from the same period last year.

Last quarter the company missed on EPS by $0.03 which was followed by a 2.93% drop in the share price the next day.

Here's a look at Intra-Cellular Therapies's past performance:

Quarter	Q3 2021	Q2 2021	Q1 2021	Q4 2020
EPS Estimate	-0.92	-0.80	-0.80	-0.85
EPS Actual	-0.95	-0.85	-0.65	-0.76
Revenue Estimate	22.12M	19.44M	16.50M	11.84M
Revenue Actual	22.21M	20.05M	15.88M	12.45M

To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.

This article was generated by Benzinga's automated content engine and reviewed by an editor.